A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants

NCT ID: NCT00655083

Last Updated: 2011-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-31
• Study Completion Date: 2009-05-31

Brief Summary

The purpose of the study is to evaluate the gastrointestinal absorption of nepadutant after single dose as oral solution (and the effect of age on its oral absorption) in infants. Oral absorption is evaluated through the drug recovery in urine.

Detailed Description

This trial aims to evaluate the oral adsorption of nepadutant (0.1 or 0.5 mg/Kg given as one single dose as oral solution) in infants divided in three age strata (from 6 to 24 weeks old). Oral absorption is evaluated by measuring the amount of nepadutant in the urine output collected during the 24 hours after oral administration with special diapers.

Safety and tolerability of the drug will be evaluated by monitoring any changes in signs/symptoms at medical examination and vital signs during the fist 4 hours post-dose in the Hospital site and then by the parents at home up to 24 hours and 1 week post nepadutant administration.

Conditions

Infantile Colic; Infantile Functional Gastrointestinal Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Nepadutant 0.1 mg/kg

Group Type: EXPERIMENTAL

Nepadutant

Intervention Type: DRUG

0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)

2

Nepadutant 0.5 mg/kg

Group Type: EXPERIMENTAL

Nepadutant

Intervention Type: DRUG

0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)

Interventions

Nepadutant

0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)

Intervention Type: DRUG

Nepadutant

0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Subjects will be eligible for inclusion in the study if they meet all of the following criteria:

• Infants with a history consistent with a diagnosis of colic or other functional gastrointestinal disorders
• Age >6 weeks and < 24 weeks
• At least 44 weeks post-conceptual age at enrolment
• Normal growth
• Informed consent by parents (one or both) or legal guardian
• Caregiver available to be trained in collection and storage of used diapers
• Caregiver available to record feeding episodes and defecations on the diary

Exclusion Criteria

Subjects will be excluded from the study if they meet any of the following criteria:

• Clinical evidence of major cardiovascular, respiratory, renal, hepatic, endocrine, metabolic, gastrointestinal (excluding infantile colic and other functional gastrointestinal disorders, unless associated to symptoms which are likely to interfere with drug absorption, e.g. frequent vomiting), haematological, severe dermatological or neurological pathology or other diseases;
• Previous major surgery or blood loss
• Intake of antimuscarinic drugs, simethicone, or dimethicone 24 hours before study treatment administration.

• Minimum Eligible Age: 6 Weeks
• Maximum Eligible Age: 24 Weeks
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Menarini Group

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jeffrey L Blumer, MD, PHD

Role: STUDY_CHAIR

Rainbow Babies and Children's Hospital

Locations

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Kosair Charities Pediatric Clinical Rsearch Unit University of Louisville

Louisville, Kentucky, United States

Rainbow Babies and Children's Hospital

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

Oral absorption

Identifier Type: -

Identifier Source: secondary_id

of Nepadutant in Infants

Identifier Type: -

Identifier Source: secondary_id

NIC 02

Identifier Type: -

Identifier Source: org_study_id